Gilmelisib

N/A

Report date: 2025/03/26 11:26:53
NME

Base Information

Drug NameGilmelisib
Drug Alias NameTQ-B3525TQ-B-3525
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionPhosphatidylinositol 3 kinase alpha inhibitorsPhosphatidylinositol 3 kinase delta inhibitors
TargetsPhosphatidylinositol 3 kinase alphaPhosphatidylinositol 3 kinase delta
Therapy Area/IndicationsSolid tumoursRenal Insufficiency, ChronicUterine Cervical Neoplasms +[14] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesJiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesNanjing Shunxin Pharmaceuticals Co Ltd Of Chiatai Tianqing Pharmaceutical GroupJiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumoursRenal Insufficiency, ChronicLymphoma, T-Cell, Peripheral +[6] 
Inactive IndicationsUterine Cervical NeoplasmsEndometrial NeoplasmsCarcinoma, Non-Small-Cell Lung +[8] 

Other Information

ATC CodeN/A
Related LinksN/A